Last updated: February 7, 2025
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Overall Status: Active - Recruiting
Phase
N/A
Condition
Colorectal Cancer
Rectal Cancer
Cancer
Treatment
Standard Colonoscopy
Clinical Study ID
NCT05355363
22.179
Ages 45-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients 45-80 who underwent colonoscopy from 2009 to 2022 at the MontrealUniversity Hospital Center (CHUM) with 1+ SL or HGD detected at index colonoscopyand lacking follow-up within or beyond the surveillance interval recommended by 2020USMSTF guidelines.
Exclusion
Exclusion Criteria:
- Patients with a diagnosis of inflammatory bowel disease;
- Hereditary CRC syndromes;
- CRC at index colonoscopy;
- Serrated polyposis syndrome;
- Life expectancy too short to benefit from colonoscopy;
- Follow-up colonoscopy not yet due according to USMSTF guidelines. Patients withconcomitant HRA and SL at index will be invited to participate if the index (orlast) colonoscopy was performed more than 1 year ago. This is based on the highrates of HRA we identified in our retrospective study posing increased risksfor these patients.
Study Design
Total Participants: 730
Treatment Group(s): 1
Primary Treatment: Standard Colonoscopy
Phase:
Study Start date:
February 27, 2023
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Centre Hospitalier de l'Université de Montréal
Montréal, Quebec
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.